← Back to Clinical Trials
Recruiting NCT03712774

NCT03712774 Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant or Definitive Chemoradiation in Patients With Esophageal Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03712774
Status Recruiting
Phase
Sponsor Ludwig-Maximilians - University of Munich
Condition Quality of Life
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2018-10-12
Primary Completion 2021-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
EORTC QLQ C30EORTC QLQ OES-18EORTC OG-25

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2018-10-12 with a primary completion date of 2021-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Prospective observational study to evaluate the Quality of life based on standardized EORTC questionaires as well as toxicities, functional and oncological outcomes in patients treated with neoadjuvant or definitive chemoradiation for esophageal Cancer.

Eligibility Criteria

Inclusion Criteria: * histologically proven esophageal Cancer (SCC or adenocarcinoma) without distant metastases (except supraclavicular nodes) * indication for neoadjuvant or definitive chemoradiation using either cisplatin/5-FU or carboplatin/paclitaxel with curative intent * age \>= 18 years * written informed consent * ability to answer the standardized questionaires according to the treating physician Exclusion Criteria: * age \< 18 years * Treatment with palliative intent * distant metastases (except supraclavicular nodes) * second malignancy * Prior systemic treatment for esophageal Cancer * Treatment in an interventional study

Contact & Investigator

Central Contact

Falk Roeder, MD

✉ Falk.Roeder@t-online.de

📞 +49 89 4400

Principal Investigator

Falk Roeder, MD

PRINCIPAL INVESTIGATOR

Ludwig-Maximilians Universität München

Frequently Asked Questions

Who can join the NCT03712774 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Quality of Life. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03712774 currently recruiting?

Yes, NCT03712774 is actively recruiting participants. Contact the research team at Falk.Roeder@t-online.de for enrollment information.

Where is the NCT03712774 trial being conducted?

This trial is being conducted at Munich, Germany.

Who is sponsoring the NCT03712774 clinical trial?

NCT03712774 is sponsored by Ludwig-Maximilians - University of Munich. The principal investigator is Falk Roeder, MD at Ludwig-Maximilians Universität München. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology